SCHEMBL15570432

SCHEMBL15570432

O=CC=C1c2ccccc2C=Cc2ccccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.45
KMT2A Q03164 6/20 0.45
LMNA P02545 5/20 0.45
MAPT P10636 4/20 0.45
KDM4E B2RXH2 3/20 0.45
ALOX15 P16050 2/20 0.45
BCHE P06276 2/20 0.45
POLB P06746 2/20 0.45
PTPRC P08575 2/20 0.45
THRB P10828 2/20 0.45
CES1 P23141 2/20 0.45
RECQL P46063 2/20 0.45
IDO1 P14902 2/20 0.45
ALDH1A1 P00352 2/20 0.45
HSD17B10 Q99714 2/20 0.45
PKM P14618 1/20 0.45
HPGD P15428 1/20 0.45
PTPN1 P18031 1/20 0.45
ACHE P22303 1/20 0.45
PTPN22 Q9Y2R2 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29773476 0.83 MEN1 (0.43) MEN1KMT2ALMNAMAPTKDM4E
SCHEMBL8872692 0.83 MEN1 (0.43) MEN1KMT2ALMNAMAPTKDM4E
SCHEMBL3769766 0.74 MEN1 (0.55) MEN1KMT2ALMNAMAPTKDM4E
SCHEMBL7325069 0.71 LMNA (0.50) MEN1KMT2ALMNAMAPTKDM4E
SCHEMBL8921555 0.71 CES1 (0.52) MEN1KMT2ALMNAMAPTKDM4E
SCHEMBL9421176 0.71 TOP1 (0.41) MEN1KMT2ALMNAKDM4EALOX15
SCHEMBL17305923 0.71 MAOA (0.52) MEN1KMT2ALMNAMAPTKDM4E
SCHEMBL7180359 0.71 MEN1 (0.53) MEN1KMT2ALMNAMAPTKDM4E
SCHEMBL2018253 0.70 HTR1A (0.49) MEN1KMT2ALMNAMAPTKDM4E
SCHEMBL29454416 0.70 MEN1 (0.42) MEN1KMT2ALMNAMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150344407-A1 FENDILINE DERIVATIVES AND METHODS OF USE THEREOF AVIARA PHARMACEUTICALS, INC. 2015-12-03 US disclosed
WO-2014031755-A1 FENDILINE DERIVATIVES AND METHODS OF USE THEREOF THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2014-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150344407-A1 FENDILINE DERIVATIVES AND METHODS OF USE THEREOF KRAS, RASSF5, RASSF2 MEN1 760/4885KMT2A 3273/4885LMNA 2538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.